Buy Vonjo (pacritinib)

What is Vonjo (pacritinib) for?

Vonjo (pacritinib) is a kinase inhibitor indicated to treat adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10^9/L.^[1]

It is available in capsule form, each containing 100 mg pacritinib.^[1]

How does Vonjo (pacritinib) work?

The active ingredient in Vonjo, pacritinib, is a kinase inhibitor. Kinase inhibitors can block a type of enzyme called kinase. Vonjo targets the enzymes JAK2 and IRAK1, which are responsible for blood cell growth and development and immune responses. Mutations in these enzymes are linked to the development of diseases such as myelofibrosis and other blood-related diseases.^[2]

Vonjo is designed so that it does not target the enzyme JAK1, which most other JAK2 inhibitors do. Inhibition of JAK1 has been found to cause immune dysfunction and lymphomas, and may also worsen thrombocytopenia and anemia.^[2]

When taken, Vonjo can bind to and target JAK2 and IRAK1, which may lead to shrinkage of the spleen and reduce symptoms.^[3]

Where has Vonjo (pacritinib) been approved?

Vonjo (pacritinib) was approved for the treatment of adults with myelofibrosis and thrombocytopenia by:

• The Food and Drug Administration (FDA), USA on February 28, 2022.^[3]

This drug was approved with accelerated approval, for which the manufacturer is required to perform a confirmatory trial. Results are expected mid 2025.^[3]

Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.

How is Vonjo (pacritinib) taken?

The standard dosage is:^[1]

• 200 mg (two capsules) taken orally twice a day

You can take the capsules with or without food. Swallow the capsules whole.^[1]

Before starting treatment and during treatment with Vonjo, your health will be monitored.^[1]

If you are on different kinase inhibitors, you should taper or discontinue treatment according to how it is prescribed in the official prescribing information of that drug.^[1]

In case you experience adverse effects, the dosage should be modified.^[1]

Complete information about Vonjo (pacritinib) dosage (modifications) and administration can be found in the official prescribing information listed in our references section.^[1]

Note: Please consult with your treating doctor for personalised dosing.

Are there any known adverse reactions or side effects of Vonjo (pacritinib)?

Common adverse reactions

The most common side effects (≥20% of patients) listed in the prescribing information include:^[1]

• Diarrhea
• Thrombocytopenia
• Nausea
• Anemia
• Peripheral edema

Serious adverse reactions

The serious adverse reactions listed in the prescribing information include:^[1]

• Hemorrhage
• Diarrhea
• Thrombocytopenia
• Prolonged QT interval
• Major adverse heart problems
• Thrombosis
• Increased risk of lymphoma and other malignancies
• Risk of infections

Use in a specific population

It is not known if Vonjo will harm your unborn baby. Talk to your treating doctor if you are pregnant or planning to become pregnant. It is not known if Vonjo passes into your breast milk.It is advised to not breastfeed during treatment and for 2 weeks after your last dose.^[1]

Do not use Vonjo if you have moderate or severe liver or kidney problems.^[1]

For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information.^[1]

References

1. Full prescribing information [FDA]: Vonjo (pacritinib) [PDF] CTI BioPharma, Feb 2022

2. Pacritinib
CTI BioPharma, cited Mar 2022

3. CTI BioPharma Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia
CTI BioPharma press release, Feb 2022